 |
|
Financial Conflict of Interest Disclosure and Voting Patterns at Food and Drug Administration Drug Advisory Committee Meetings
Peter Lurie, MD, MPH;
Cristina M. Almeida, MD, MPH;
Nicholas Stine, BA;
Alexander R. Stine, SM;
Sidney M. Wolfe, MD
JAMA. 2006;295:1921-1928.
Context In January 2002, the US Food and Drug Administration (FDA) issued a draft guidance requiring more detailed financial conflict of interest disclosure at advisory committee meetings.
Objectives To characterize financial conflict disclosures at drug-related meetings, and to assess the relationship between conflicts and voting behavior at meetings that considered specific products.
Design and Setting Cross-sectional study using agendas and transcripts from all FDA Drug Advisory Committee meetings (2001-2004) listed on the FDA Web site.
Main Outcome Measures Conflict rates, type, and size. The relationship between having a conflict and voting in favor of the index drug was described for each voter using Mantel-Haenszel relative risks and Monte Carlo simulations; Spearman rho was used for a meeting-level analysis comparing rates of conflict with voting patterns. The impact of the removal of persons with conflicts of interest on the vote margins was also evaluated.
Results A total of 221 meetings held by 16 advisory committees were included in the study. In 73% of the meetings, at least 1 advisory committee member or voting consultant disclosed a conflict; only 1% of advisory committee members were recused. For advisory committee members (n = 1957) and voting consultants combined (n = 990), 28% (n = 825) disclosed a conflict. The most commonly specified conflicts were consulting arrangements, contracts/grants, and investments. Nineteen percent of consulting arrangements involved over $10 000, 23% of contracts/grants exceeded $100 000, and 30% of investments were over $25 000. The meeting-level analysis did not show a statistically significant relationship between conflict rates ("index conflict," "competitor conflict," or "any conflict") and voting patterns, but a weak, statistically significant positive relationship was apparent for competitor conflict and any conflict in the Mantel-Haenszel analyses. The Monte Carlo analyses produced similar findings in the competitor conflict analysis only. In all 3 conflict categories, the exclusion of advisory committee members and voting consultants with conflicts would have produced margins less favorable to the index drug in the majority of meetings, but this would not have changed whether the majority favored or opposed the drug.
Conclusions Disclosures of conflicts of interest at drug advisory committee meetings are common, often of considerable monetary value, and rarely result in recusal of advisory committee members. A weak relationship between certain types of conflicts and voting behaviors was detected, but excluding advisory committee members and voting consultants with conflicts would not have altered the overall vote outcome at any meeting studied.
Author Affiliations: Public Citizen’s Health Research Group, Washington, DC (Drs Lurie, Almeida, and Wolfe and Mr N. Stine), and Department of Earth and Planetary Science, University of California, Berkeley (Mr A. Stine).
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Evaluating solutions to sponsorship bias
Doucet and Sismondo
J. Med. Ethics 2008;34:627-630.
ABSTRACT
| FULL TEXT
Standards in dementia care
Gogol
Age Ageing 2007;36:599-600.
FULL TEXT
Disclosure Of Medical Injury To Patients: An Improbable Risk Management Strategy
Studdert et al.
Health Aff (Millwood) 2007;26:215-226.
ABSTRACT
| FULL TEXT
FDA to clarify rules on advisory committee members.
Tanne
BMJ 2006;333:278-278.
FULL TEXT
Conflicts of interest are common at FDA.
Lenzer
BMJ 2006;332:991-991.
FULL TEXT
|
